Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Saputo inc. à la conférence « Back to School » de ScotiabankCompanies: ScotiabankMONTRÉAL, 09 sept. 2026 -- Saputo inc. (TSX: SAP) a annoncé aujourd’hui que M. Carl Colizza, président et chef de la direction, fera une présentation à la conférence « Back to School » de Scotiabank qui se tiendra à Toronto, en Ontario, le mercredi 16 septembre 2026, à 11 h 15 (heure de l’Est).
- Saputo Inc. at the Scotiabank Back to School ConferenceCompanies: ScotiabankSaputo Inc. (TSX: SAP) today announced that Mr. Carl Colizza, President and CEO, will present at the Scotiabank Back to School Conference in Toronto, Ontario, on Wednesday, September 16, 2026, at 11:15 a.m. (Eastern Time).
- The 11th Belt and Road Summit opened todayHONG KONG, Sept 9, 2026 - The 11th Belt and Road Summit, co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), opened today at the Hong Kong Convention and Exhibition Centre in Wan Chai. Under the theme Advancing High-Quality Development • Embarking on a New Journey, the Summit brings together more than 100 government officials, business leaders and professionals from Belt and Road countries and regions to jointly explore new opportunities in high-quality Belt and Road development, to promote cross-regional trade and industrial matching, and accelerate the implementation of concrete outcomes. The Summit has achieved significant results in promoting international cooperation and facilitating business partnerships. Multiple memoranda of understanding (MoUs) and agreements were signed on the first day, spanning sectors such as finance, professional services, industry and construction, and involving organisations from the Chinese Mainland, Australia, Indonesia, Kazakhstan, Laos, Malaysia, Oman, Qatar and Uzbekistan. More MoUs and agreements are expected to be signed tomorrow, helping to transform connections forged and ideas exchanged at the Summit into tangible collaborations and business opportunities. The Opening Session featured opening remarks by John Lee, Chief Executive of the HKSAR, and welcome remarks by Professor Frederick Ma, Chairman of the HKTDC. Abdulla Aripov, Prime Minister of Uzbekistan, Carolina Cosse, Vice President of Uruguay, and Saleumxay Kommasith, Deputy Prime Minister of Laos, delivered special addresses. Yan Dong, Vice Minister of the Ministry of Commerce of the People’s Republic of China, and Li Zhen, Vice Chairman of the State-owned Assets Supervision and Administration Commission of the State Council of the People’s Republic of China, delivered special remarks. John Lee said in his opening remarks: “Hong Kong is an ideal two-way springboard for Mainland enterprises expanding overseas, and for international companies looking to enter the Mainland market. Our GoGlobal Task Force, established last October, has assisted more than 300 Mainland enterprises in establishing or expanding their businesses in Hong Kong, and our world-class professional services are ready to support their overseas expansion plans.” He continued: “In addition to strengthening our relations with traditional partners, Hong Kong continues to expand our network of friends along the Belt and Road. Since 2022, I have led high-level business delegations to explore opportunities in 13 Belt and Road countries across ASEAN, the Middle East, and Central Asia. These missions delivered over 250 MOUs (Memorandum of Understanding) and other agreements, from policy co-ordination and trade and investment, to expanded connectivity and support for companies. They underline Hong Kong's long-standing focus on opening new markets, forming new partnerships and advancing regional co-operation.” John Lee, Chief Executive of the HKSAR, delivered opening remarks at the Opening Session. Professor Frederick Ma said in his welcome remarks: “In a world full of risks and uncertainties, diversification is a necessity, not a choice. We must seize new opportunities even as we navigate new challenges. That is why the Belt and Road Initiative has never been more relevant. At its core, the Initiative is about forging new connections, turning potential into opportunity and opportunity into tangible development that benefits communities around the world. ASEAN, Central Asia, the Middle East, Africa and Latin America are among the regions with the greatest growth potential. As an important commercial platform for the Belt and Road Initiative, Hong Kong will continue to leverage its unique strength in connecting the Chinese Mainland with global markets. This year's Summit introduces new thematic zones, including the ‘GoGlobal Connect’ zone, bringing Hong Kong’s professional services expertise to support enterprises to expand internationally and capture new opportunities in global markets.” Professor Frederick Ma, Chairman of the HKTDC, delivered welcome remarks at the Opening Session. Abdulla Aripov said in his special address: “Uzbekistan regards the Belt and Road Initiative as an effective platform for reviving the ancient Silk Road in a modern format and advancing cooperation in trade, transport, investment, industrial collaboration, technology, capital, and human resources. Today, our cooperation with Belt and Road countries has been elevated to comprehensive strategic partnerships. Undoubtedly, the close and trusting relationship between the leaders of our two nations, President Shavkat Mirziyoyev of the Republic of Uzbekistan and President Xi Jinping of the People’s Republic of China, plays a crucial role in this development. Uzbekistan is ready to be a reliable, long-term partner in building a Belt and Road community of shared development and prosperity. We invite all participants to join us in creating new manufacturing and technology value chains in Uzbekistan, expanding investment and financial cooperation, and using Uzbekistan as a gateway to Central Asia and neighboring markets.” Abdulla Aripov, Prime Minister of Uzbekistan, delivered a keynote special address at the Opening Session. Carolina Cosse said in her special address: “In 2018, Uruguay was the first country in Mercosur to formally express its support of the Belt and Road Initiative. We were also the first country in South America to sign a memorandum of understanding on the Belt and Road Initiative with the People's Republic of China. The BRI pillars of infrastructure, connectivity, trade facilitation, and financial integration aligned with Uruguay's long-standing belief in multilateral cooperation and free trade. Uruguay stands ready to translate our commitment to the Belt and Road into tangible cooperative outcomes with Hong Kong and with all partners assembled here. thus facilitating capital flows, trade financing, and project development into Latin America and Asia.” Carolina Cosse, Vice President of Uruguay, delivered a keynote special address at the Opening Session. Saleumxay Kommasith said in his special address: “We regard the Belt and Road Initiative as a vital cornerstone of our long-term country development agenda. It has contributed significantly to expanding trade, attracting foreign direct investment, developing modern infrastructure, and strengthening people-to-people connection across the border.The most tangible evidence under the framework of high-quality BRI cooperation is the historic achievement of the Lao-China Railway since its launch in 2021. Today, it has facilitated over 70 million passengers and transported over 90 million metric tons of freight, contributing to expanding our trade profile from just 13 regional commodity categories to more than 4,000 types of products today. Driven by this advanced connectivity, bilateral trade between Lao PDR and China has achieved a new milestone, surpassing 9.8 billion US dollars. It has successfully transformed the Lao PDR from a landlocked country into a land-linked regional logistics hub. It has significantly reduced logistics costs and integrated Lao PDR into the regional supply chain.” Saleumxay Kommasith, Deputy Prime Minister of Laos, delivered a keynote special address at the Opening Session. Yan Dong said in his special remarks: “We will support Hong Kong in leveraging its professional service advantages to participate deeply in Belt and Road cooperation projects, guide Hong Kong enterprises to provide professional services such as legal consultation, financial and insurance services, mediation and arbitration for project implementation, strengthen information exchange between Chinese Mainland and Hong Kong enterprises, with the aim of achieving mutual benefit and win-win outcomes through joint ventures and other means.” Yan Dong, Vice Minister of Minister of Commerce of the People’s Republic of China, delivered a special remarks at the Opening Session. Li Zhen said in his special remarks: “We support Hong Kong and Macao in better integrating into the new policies for national development - we guide central state-owned enterprises to establish treasury and trade centres, research and development institutions and international business headquarters in Hong Kong; and we support Hong Kong in consolidating and enhancing its status as an international financial, shipping and trade centre, as well as an international aviation hub. Looking ahead, drawing on the unique advantages of ‘One Country, Two Systems’, Hong Kong is bound to play a significant role as a ‘super connector’ and ‘super value-adder’” Li Zhen, Vice Chairman of the State-owned Assets Supervision and Administration Commission of the State Council of the People’s Republic of China, delivered a special remarks at the Opening Session. Government and business leaders explore new avenues for cross-regional cooperation Against a backdrop of a reshaped global trade landscape, ongoing supply chain reconfiguration and increasing geopolitical uncertainty, enhancing trade and investment resilience has become a key priority for economies worldwide. Following the Opening Session, the Policy Dialogue, themed Building Resilient Trade and Investment Frameworks in a Diverse Global Landscape was moderated by Algernon Yau, Secretary for Commerce and Economic Development of the HKSAR. Distinguished government officials participating as speakers included Khandakar Abdul Muktadir, Minister for Commerce, Industries, Textiles and Jute, Bangladesh, Arman Shakkaliyev, Minister of Trade and Integration, Kazakhstan, Wasantha Samarasinghe, Minister of Trade, Commerce, Food Security and Co-operative Development, Sri Lanka, Filipus Nino Pereira, Minister of Commerce and Industry, Timor-Leste, Dr Ahmed bin Mohammed Al-Sayed, Minister of State for Foreign Trade Affairs, Qatar, and Dr Kirida Bhaopichitr, Vice Minister for Commerce, Thailand. They exchanged views on promoting cross-border trade, facilitating investment flows and strengthening economic resilience. The Policy Dialogue, themed Building Resilient Trade and Investment Frameworks in a Diverse Global Landscape, was chaired by Algernon Yau, Secretary for Commerce and Economic Development of the HKSAR. Senior officials from Bangladesh, Kazakhstan, Sri Lanka, Timor-Leste, Qatar and Thailand were invited to discuss ways to strengthen cross-border trade and investment cooperation and enhance economic resilience. The Business Plenary I: Harnessing Business Opportunities for Sustainable Growth and Shared Prosperity session was chaired by Dr Victor K Fung, Chairman of Fung Investments. Joining the discussion were Dr Jonathan Choi, Chairman of Sunwah Group; Shinta Widjaja Kamdani, CEO of Sintesa Group and Chairman of Indonesian Employer Association: Vikrom Kromadit, CEO of Amata Corporation PCL; Farkhad Rashidovich Okhonov, Member of the Board of Directors, Chairman of the Management Board of Halyk Finance, Somboun Phongsavanh, Chairman of Shareholder Committee at Phongsavanh Group, and Professor Zhou Yong, Chairman of Jiangsu SOHO Holdings Group Co., Ltd. The speakers explored the development potential of ASEAN and Central Asian markets, and discussed how businesses can seize a new wave of regional growth opportunities through cross-border investment, industrial collaboration and innovation-driven development. The first-day Business Plenary: Harnessing Business Opportunities for Sustainable Growth and Shared Prosperity, brought together business leaders from ASEAN, Central Asia and the Chinese Mainland to explore new opportunities in cross-border investment, industrial cooperation and sustainable development, jointly driving regional economic integration and prosperity. The first-day Business Plenary: Harnessing Business Opportunities for Sustainable Growth and Shared Prosperity, brought together business leaders from ASEAN, Central Asia and the Chinese Mainland to explore new opportunities in cross-border investment, industrial cooperation and sustainable development, jointly driving regional economic integration and prosperity. In addition to in-depth discussions on a wide range of topics, the Summit also provided valuable networking opportunities, enabling participants to forge new connections and explore potential partnerships. At a luncheon, Paul Chan, Financial Secretary of the HKSAR, delivered welcome remarks, while Wang Shuguang, Vice Chairman of the Board, President and Member of the Management Committee of China International Capital Corporation Limited, gave the opening remarks. Dr Kao Kim Hourn, Secretary-General of ASEAN, delivered the keynote address. Dr. Kao said: “Hong Kong can link ASEAN's growing and resilient pipeline of sustainable investment opportunities with global capital. The opportunity is to bridge two sides of the equation: ASEAN's growing pipeline of green, circular, blue, and digital economy projects, and the capital, expertise, and financing capabilities needed to bring those opportunities to reality. Together with Belt and Road partners, we can turn sustainable initiatives into bankable projects, and bankable projects into a greener, more connected, and more resilient ASEAN—and, of course, offer opportunities to all partners, including Hong Kong, China.” A cocktail reception will be held this evening, featuring special remarks by Paul Lam, Secretary for Justice of the HKSAR, welcome remarks by Prof Frederick Ma, Chairman of the HKTDC, and opening remarks by Wang Huabin, Deputy Chief Executive of Bank of China (Hong Kong) Ltd. Bringing together government and business leaders from around the world, the reception will foster exchanges and mutual learning, while laying the groundwork for broader collaboration, business matching and partnership opportunities on the following day. New GoGlobal, Central Asia and Middle East Chapters spotlight opportunities in emerging markets In support of the national strategy to encourage enterprises to pursue high-level going global, the HKTDC, as a member of the GoGlobal Task Force established by the HKSAR Government, introduced a new GoGlobal Chapter at this year’s Summit, creating a one-stop platform for networking and business matching to support enterprises in exploring international markets. On the first day, the Thematic Breakout Session Hong Kong: Super Connector ・ World-class Springboard – Professional Services Empowering Global Expansion was staged, co-organised with the Department of Justice of the HKSAR Government. The session opened with welcome remarks by Paul Lam, Secretary for Justice of the HKSAR, followed by a keynote address by Umiraliyev Zhandos Zhanibekovich, First Deputy Prosecutor General of the Republic of Kazakhstan, and a moderated session by other industry leaders, who examined how Hong Kong’s legal, financial and professional services can help enterprises expand overseas through Hong Kong. Tomorrow’s Thematic Breakout Session, Chinese Mainland Enterprises Going Global: Driving Mutual Growth Across Belt and Road Economies, will begin with welcome remarks by Algernon Yau, Secretary for Commerce and Economic Development of the HKSAR, followed by a panel discussion, sharing practical insights on expanding businesses into overseas markets. Beyond the Thematic Breakout Sessions, the Summit offers comprehensive support for enterprises seeking international expansion through newly introduced initiatives, including the GoGlobal Connect Zone, GoGlobal-themed roundtable discussions, deal-making sessions for global investment projects, and the GoGlobal Business Study Mission, fully leveraging Hong Kong’s role as the preferred platform for enterprises going global. Building on Hong Kong’s recent progress in cultivating emerging markets such as Central Asia and the Middle East, this year’s Summit features a dedicated Central Asia Chapter and a Middle East Chapter, focusing on investment opportunities and development potential in these markets, driving cross-regional cooperation and project implementation. During the first day of the Signature Projects Session, Bakhtiyar Mukhametkaliyev, Vice Minister of Artificial Intelligence and Digital Development of the Republic of Kazakhstan, and Dr Bayan Konirbayev, Chief Digital & AI Officer of Alatau City Authority, presented major development projects including Alatau City and the Data Center Valley, showcasing opportunities across innovation and technology, smart city development, infrastructure and professional services. The Project Investment Sessions over the next two days will respectively explore the investment opportunities arising from development projects in Central Asia and the Middle East. In addition, new Central Asia and Middle East Zones have been established in the exhibition area, bringing together consulates, organisations and business representatives from the respective regions to showcase investment projects and commercial opportunities. Project matching creates a platform for cooperation while exhibition zones connect global business opportunities The Summit fosters cross-regional partnerships among enterprises, investors and professional service providers through investment project presentations, business matching and exhibition platforms. The Summit continues to feature the Project Investment Sessions, Belt and Road Summit Deal-Making and Exhibition Zone, covering more than 300 investment projects and facilitating over 800 one-to-one business matching meetings, helping participants uncover investment and collaboration opportunities. The Project Investment Sessions continue to focus on key areas including energy, natural resources and public utilities, urban development, transport and logistics infrastructure, and innovation and technology. A new session, New Market Focus: The Middle East, Africa and Latin America will showcase the investment potential and development prospects of different markets. The Belt and Road Summit Deal-Making takes place during the Summit and will be extended online to 14 and 15 September, helping participants connect with potential partners from around the world through one-on-one business matching to further facilitate project implementation. The Exhibition Zone brings together more than 120 exhibitors across multiple thematic zones, including the Hong Kong Zone, Global Investment Zone, Chinese Mainland Zone, ASEAN Zone, as well as the newly established University Zone, GreenTech Zone, GoGlobal Connect Zone, Central Asia Zone and Middle East Zone, comprehensively showcasing investment opportunities, innovative technology, and professional service solutions from diverse markets. Among the highlights, the University Zone brings together local institutions to showcase Hong Kong’s strengths in research, innovative and talent development. The GreenTech Zone focuses on innovative applications in artificial intelligence, green technology, and smart city solutions, fostering collaboration among technology companies, investors and industry stakeholders. Meanwhile, the GoGlobal Connect Zone gathers professional service providers in legal, accounting, finance, risk management, and consultancy fields to provide practical support for enterprises expanding overseas. Returning this year, the Chinese Mainland Zone and the ASEAN Zone spotlight high-potential investment projects and business opportunities, promoting cross-border exchanges and collaboration. The 11th Belt and Road Summit is supported by a strong line-up of partners and sponsors. China International Capital Corporation Limited serves as Strategic Partner, while Bank of China (Hong Kong) is the Banking Partner. Other key supporters include Standard Chartered Bank (Hong Kong) as the Cross-border Business Partner, the Hongkong and Shanghai Banking Corporation Limited as the Global Connectivity Partner, Huatai International Financial Holdings Company Limited as the Innovative Finance Partner, International Financial Centre of Oman as Diamond Sponsor, and CCB International (Holdings) Limited and China Mobile International Limited as Platinum Sponsors. Unlocking opportunities at the ASEAN Market Day held concurrently during the Belt and Road Week The Belt and Road Summit is one of the key flagship events of Belt and Road Week. Belt and Road Week features a series of activities related to the Belt and Road Initiative. With representatives of ASEAN member states coming to Hong Kong to participate in the Summit, the HKTDC will introduce a new flagship event, ASEAN Market Day, which will be held on the afternoon of 10 September. The event will feature business leaders and industry experts with extensive experience in the ASEAN market, including Anthony Lam, Group CEO and Vice-Chairman, Golden Resources Development International Limited; Dr Brian Li, Vice Chairman and Executive Vice President, Gold Peak Technology Group Limited; Clara Chan, Chief Executive Officer, Lee Kee Group; Yu Wing Keung, Managing Director, Novostal Limited and Vice President, Thai-Hong Kong Trade Association; and Aero Wong, Deputy General Manager, Commercial Banking Department, Bank of China (Hong Kong) Ltd. They will share practical insights on expanding into ASEAN markets and highlight business opportunities across the region, helping Hong Kong companies, particularly SMEs, gain a deeper understanding of market trends and grow their presence in ASEAN. Following the session, participants will be arranged to visit the ASEAN Zone at the Summit and take part in consultation sessions with representatives from the HKTDC’s offices in ASEAN and various ASEAN Consulates General and associations to exchange views, connect with potential partners and gain a deeper understanding of development opportunities in ASEAN markets. The Belt and Road Global Forum Annual Roundtable will be held on the morning of 11 September, bringing together Hong Kong, Chinese Mainland and international organisations and associations to share information, deepen exchanges and explore new opportunities for multilateral cooperation. The 11th Belt and Road Summit Date 9 to 10 September 2026 Venue Hall 5B-E, Hong Kong Convention and Exhibition Centre Websites Belt and Road Summit: https://www.beltandroadsummit.com/conference/bnr/en Programme: https://www.beltandroadsummit.com/conference/bnr/en/programme Speaker list: https://www.beltandroadsummit.com/conference/bnr/en/speaker Photo download: https://bit.ly/4cC23FI The Keynote Luncheon featured welcome remarks by Paul Chan, Financial Secretary of the HKSAR, and opening remarks by Wang Shuguang, Vice Chairman of the Board, President and Member of the Management Committee of China International Capital Corporation Limited. Dr Kao Kim Hourn, Secretary-General of ASEAN, delivered the keynote speech. As part of the Summit’s newly launched GoGlobal Chapter, the thematic breakout session, Hong Kong: Super Connector・World-class Springboard – Professional Services Empowering Global Expansion, was co-organised by the HKTDC and the Department of Justice of the HKSAR Government. Paul Lam, Secretary for Justice of the HKSAR Government, delivered welcome remarks, followed by a keynote address by Umiraliyev Zhandos Zhanibekovich, First Deputy Prosecutor General of Kazakhstan. Media Enquiries Yuan Tung Financial Relations: Louise SongTel: (852) 3428 5691Email: [email protected] Tiffany LeungTel: (852) 3428 2361Email: [email protected] Fung WongTel: (852) 3428 3122Email: [email protected] HKTDC’s Communications & Public Affairs Department: Navin LawTel: (852) 2584 4525Email: [email protected] Serena CheungTel: (852) 2584 4572Email: [email protected] Winnie KanTel: (852) 2584 4055Email: [email protected] HKTDC Media Room: https://mediaroom.hktdc.com/en About HKTDC The Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via trade publications, research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.
- TruMeritGlobal Study: Nursing Shortages Require Workforce Policy Solutions, Not Recruitment Campaigns AlonePHILADELPHIA, PA, Sept 9, 2026 - The global nursing shortage cannot be solved simply by encouraging more people to enter the profession, according to a new evidence brief from the Global Nursing Workforce Centre (GNWC), a joint initiative of the International Council of Nurses (ICN) and TruMerit®. Drawing on research from 42 countries, the brief, The Attractiveness of Nursing for Prospective and Current Nursing Students, finds that the factors influencing people to choose nursing are often the same ones that determine whether they stay. Working conditions, compensation, professional respect, career development opportunities, workplace experiences, and the ability to provide quality care all shape nursing attractiveness to current nurses as well as potential recruits. The findings suggest that countries seeking to strengthen their nursing workforce must focus not only on recruitment, but on making nursing a career people can realistically choose, enter, develop in and remain in over the long term. "Around the world, demographic shifts, displacement, climate-related challenges, geopolitical instability, and digital transformation are reshaping workforce needs," said Peter Preziosi, PhD, RN, CAE, FAAN, TruMerit President and Chief Executive Officer. "Nursing is no exception. This evidence brief offers actionable insights into what attracts people to nursing and what inspires them to stay. The message for policymakers is clear: evidence-informed workforce policies that support nurses' professional growth, well-being, and ability to deliver quality care are essential to building the resilient health systems our future depends on." ICN CEO Howard Catton said: "A sense of vocation may bring people into nursing, but it does not put food on the table, and it cannot protect nurses from burnout. The profession is being squeezed at both ends: younger generations rightly expect fair reward, flexibility, and opportunities to progress, while experienced nurses are being driven out by intolerable pressures. As a predominantly female profession, nursing must also provide decent work and genuine opportunities for women. Governments have relied on nurses' sense of vocation for too long; this evidence shows why policymakers must look seriously at what makes nursing a sustainable career." The findings underscore a critical workforce policy challenge for governments, healthcare employers, educators, and workforce planners: attracting more people into nursing will have limited impact if health systems do not also address the conditions that cause nurses to leave. The brief has been developed in line with GNWC's mission to transform global nursing workforce research into practical, evidence-based insights that support workforce planning, policy development, and sustainable health systems. What the Evidence Shows Purpose remains nursing's greatest draw. Helping others continues to be the strongest motivation for choosing the profession. Working conditions shape both recruitment and retention. Burnout, staffing shortages, workload pressures, and workplace stress discourage people from entering nursing and drive others to leave. Professional value matters. Compensation, professional respect, and public perceptions of nursing significantly influence career decisions. A new generation has new expectations. Flexibility, work-life balance, and opportunities for career growth are increasingly important factors when choosing and staying in nursing. About the Global Nursing Workforce Centre The Global Nursing Workforce Centre (GNWC) is a joint initiative of the International Council of Nurses (ICN) and TruMerit® that serves as a catalyst for evidence-based workforce policy. By transforming global nursing workforce research into actionable insights, the Centre supports policymakers, employers, educators and healthcare leaders in developing sustainable workforce solutions and stronger health systems worldwide. About TruMerit® TruMerit is a worldwide leader in healthcare workforce development with nearly 50 years of experience supporting the mobility of nurses and other healthcare workers. Formerly CGFNS International, TruMerit validates the education, training, and professional experience of internationally educated health professionals seeking authorization to practice in the United States and other countries. Through its expanded mission and the Global Health Workforce Development Institute, TruMerit advances research, standards, and certifications that strengthen the global health workforce and promote equitable, sustainable career mobility. About the International Council of Nurses The International Council of Nurses (ICN) is a federation of more than 140 national nurses associations representing millions of nurses worldwide. Operated by nurses and leading nursing internationally, ICN works to ensure quality care for all and sound health policies globally. Visit www.icn.ch. Media Contact: Emma Wright Director of Communications TruMerit [email protected] Richard Elliott Director of Communications and Events International Council of Nurses [email protected] SOURCE: TruMerit
- Neomics Institute Transforms Financial Learning with New Quantora 4.0 FrameworkAs global financial markets rapidly evolve and the sheer volume of corporate disclosures, macroeconomic data, and daily market news continues to surge, Neomics Institute has announced the advancement of its proprietary research and learning environment, Quantora 4.0. Founded in Colorado in 2019 by Dean Theron Avelis, the institute is bridging the critical gap between foundational financial education and advanced, systematic market research to help learners build comprehensive, long-term analytical capabilities.
- CMS: Initial Prescriptions for Silevimig Injection, the World's First Bispecific Antibody Against Rabies, Issued in ChinaSHENZHEN, Sept 9, 2026 - On 9 September, China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China. Dual-Epitope Neutralization with Low Dosing, Addressing Clinical Pain Points Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes (G protein epitopes I and III) of the rabies virus, which is consistent with the World Health Organization (“WHO”) recommendation for a “cocktail” therapeutic paradigm. It can effectively neutralize different viral strains or genotypes of the rabies virus, providing immediate protection before the establishment of full protection by active rabies vaccination, and building a critical line of defense against viral infection. The Product is currently the passive immunization product with the smallest dose for rabies (0.05 mg/kg); compared with human rabies immune globulin (“HRIG”), it requires less injection volume and easier administration, which can effectively reduce pain and improve compliance for patient. Manufactured using recombinant technology, the Product is non-plasma-derived and carries no risk of blood-borne infections. It can be manufactured at scale through standardized and stable processes, with controllable production costs, while offering a single active ingredient, consistent quality and minimal batch-to-batch variability. These advantages open up new possibilities for improving the safety, standardized supply and patient accessibility of rabies passive immunization products, with the potential to further increase market penetration. Initial Prescriptions Issued Within About Two Months After Approval, Academic-Driven Commercialization Platform Accelerating Value Realization Silevimig Injection was approved for marketing in China in June 2026. Following the approval, CMS worked closely with its partner Genrix Bio to advance critical workstreams including drug supply, market access and academic promotion, while integrating expert networks and market resources. The inital prescriptions were issued in China within approximately two months, accelerating the translation of innovation outcomes into a clinically accessible new treatment option. Currently, CMS has nine commercialized innovative drugs that are progressively achieving large-scale clinical application across China, accelerating the realization of the clinical value of each quality medicine. Going forward, CMS will remain focused on clinical unmet needs and continue to build a differentiated innovative product portfolio through a dual-track system of in-house R&D and collaborative R&D, accelerating accessibility of quality innovative drugs and taking concrete action to safeguard patients’ lives and health. About Rabies Rabies is an acute zoonotic disease caused by RABV, clinically characterized by aerophobia, hydrophobia, pharyngeal muscle spasms and progressive paralysis[1], with a case-fatality rate approaching 100%. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized post-exposure management, comprising wound care, vaccination and passive immunization administered as needed, remains the most effective strategy[2]. As vaccine-induced antibodies require 1-2 weeks after the first dose of vaccine injection to reach protective levels, passive immunization provides immediate coverage [1]. According to the National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure, patients with confirmed Category II exposure involving severe immunodeficiency, and patients with Category II exposure involving wounds to the head or face while the health status of the offending animal cannot be determined should receive passive immunization at the same time as the first dose of rabies vaccine[3]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% fall under Category III exposure[1]. However, due to factors such as limited awareness, high price, and restricted accessibility, only about 15% of Category III cases receive passive immunization[1]. Currently, the primary passive immunization option in China is HRIG. However, HRIG must be sourced from healthy donors, making it difficult and costly to obtain. Furthermore, it carries potential risks of blood-borne infections. This has led to a low penetration rate of passive immunization products in China. More Information about Silevimig Injection In a Phase III clinical trial in adults in China, Silevimig Injection met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with HRIG, the currently most used passive immunization product in China. The Product provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination. In addition, a Phase III clinical trial in children and adolescents aged 2 to <18 years is currently ongoing in China. The Product has been granted a patent in China. In September 2025, the Group through subsidiaries of the Company entered into an Exclusive Collaboration Agreement (the “Agreement”) with Chongqing Genrix Biopharmaceutical Co., Ltd. In accordance with the Agreement, the Group has obtained exclusive commercialization rights for the Product in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration term extends until ten years after the Product receives the marketing approval in Mainland China (the “Initial Term for the Product”). Unless terminated or dissolved under the terms set forth in the Agreement, the Agreement will automatically renew for successive ten-year periods upon expiration of the Initial Term for the Product. About CMS CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value. CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network. CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development. Reference: 1. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf 2. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis [J]. Chinese Journal of Preventive Medicine, 2019, 53(7): 668–679. DOI: 10.3760/cma.j.issn.0253-9624.2019.07.004 3. Chinese Center for Disease Control and Prevention. National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdf CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: [email protected]: https://web.cms.net.cn/en/home/
- CMS: Initial Prescriptions for Silevimig Injection, the World's First Bispecific Antibody Against Rabies, Issued in ChinaSHENZHEN, Sept 9, 2026 - On 9 September, China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China. Dual-Epitope Neutralization with Low Dosing, Addressing Clinical Pain Points Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes (G protein epitopes I and III) of the rabies virus, which is consistent with the World Health Organization (“WHO”) recommendation for a “cocktail” therapeutic paradigm. It can effectively neutralize different viral strains or genotypes of the rabies virus, providing immediate protection before the establishment of full protection by active rabies vaccination, and building a critical line of defense against viral infection. The Product is currently the passive immunization product with the smallest dose for rabies (0.05 mg/kg); compared with human rabies immune globulin (“HRIG”), it requires less injection volume and easier administration, which can effectively reduce pain and improve compliance for patient. Manufactured using recombinant technology, the Product is non-plasma-derived and carries no risk of blood-borne infections. It can be manufactured at scale through standardized and stable processes, with controllable production costs, while offering a single active ingredient, consistent quality and minimal batch-to-batch variability. These advantages open up new possibilities for improving the safety, standardized supply and patient accessibility of rabies passive immunization products, with the potential to further increase market penetration. Initial Prescriptions Issued Within About Two Months After Approval, Academic-Driven Commercialization Platform Accelerating Value Realization Silevimig Injection was approved for marketing in China in June 2026. Following the approval, CMS worked closely with its partner Genrix Bio to advance critical workstreams including drug supply, market access and academic promotion, while integrating expert networks and market resources. The inital prescriptions were issued in China within approximately two months, accelerating the translation of innovation outcomes into a clinically accessible new treatment option. Currently, CMS has nine commercialized innovative drugs that are progressively achieving large-scale clinical application across China, accelerating the realization of the clinical value of each quality medicine. Going forward, CMS will remain focused on clinical unmet needs and continue to build a differentiated innovative product portfolio through a dual-track system of in-house R&D and collaborative R&D, accelerating accessibility of quality innovative drugs and taking concrete action to safeguard patients’ lives and health. About Rabies Rabies is an acute zoonotic disease caused by RABV, clinically characterized by aerophobia, hydrophobia, pharyngeal muscle spasms and progressive paralysis[1], with a case-fatality rate approaching 100%. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized post-exposure management, comprising wound care, vaccination and passive immunization administered as needed, remains the most effective strategy[2]. As vaccine-induced antibodies require 1-2 weeks after the first dose of vaccine injection to reach protective levels, passive immunization provides immediate coverage [1]. According to the National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure, patients with confirmed Category II exposure involving severe immunodeficiency, and patients with Category II exposure involving wounds to the head or face while the health status of the offending animal cannot be determined should receive passive immunization at the same time as the first dose of rabies vaccine[3]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% fall under Category III exposure[1]. However, due to factors such as limited awareness, high price, and restricted accessibility, only about 15% of Category III cases receive passive immunization[1]. Currently, the primary passive immunization option in China is HRIG. However, HRIG must be sourced from healthy donors, making it difficult and costly to obtain. Furthermore, it carries potential risks of blood-borne infections. This has led to a low penetration rate of passive immunization products in China. More Information about Silevimig Injection In a Phase III clinical trial in adults in China, Silevimig Injection met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with HRIG, the currently most used passive immunization product in China. The Product provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination. In addition, a Phase III clinical trial in children and adolescents aged 2 to <18 years is currently ongoing in China. The Product has been granted a patent in China. In September 2025, the Group through subsidiaries of the Company entered into an Exclusive Collaboration Agreement (the “Agreement”) with Chongqing Genrix Biopharmaceutical Co., Ltd. In accordance with the Agreement, the Group has obtained exclusive commercialization rights for the Product in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration term extends until ten years after the Product receives the marketing approval in Mainland China (the “Initial Term for the Product”). Unless terminated or dissolved under the terms set forth in the Agreement, the Agreement will automatically renew for successive ten-year periods upon expiration of the Initial Term for the Product. About CMS CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value. CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network. CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development. Reference: 1. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf 2. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis [J]. Chinese Journal of Preventive Medicine, 2019, 53(7): 668–679. DOI: 10.3760/cma.j.issn.0253-9624.2019.07.004 3. Chinese Center for Disease Control and Prevention. National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdf CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: [email protected] Website: https://web.cms.net.cn/en/home/
- ReviztoRevizto Academy celebrates two years with more than 13,500 certifications awardedAs construction's skills needs evolve, Revizto Academy is helping connect practical digital learning with the realities of modern project delivery. — Revizto, the leading collaboration platform for the architecture, engineering,...
- GomSpace and KFUPM Sign MoU to Explore Strategic Cooperation in Space Technology and Satellite MissionsStrategic cooperation aims to advance satellite capabilities, foster talent development, and support Saudi Arabia's growing space ecosystem. — GomSpace A/S and King Fahd University of Petroleum & Minerals (KFUPM) have signed a Memorandum of...
- Universitas Brawijaya Forest operates thermal drone to strengthen fire mitigationMALANG, E. JAVA, Indonesia, Sept 9, 2026 - Although this thermal drone helps in detection, its flight duration is limitedlasting a maximum of about 30 minutes per flight. Conducting longer patrols requires additional batteries and a schedule of two patrols per week. Universitas Brawijaya (UB) Forest management is strengthening forest fire mitigation techniques by deploying a Matrice 30T thermal drone which capable of detecting hotspots from the air within the area. Muhammad Yusuf, the Coordinator for Forest Area Protection and Supervision at UB Forest, stated in an official release received in Malang City, East Java, on Thursday, that the technology assists personnel in obtaining preliminary information regarding suspected fire hotspots before field interventions are carried out. "If a hotspot is detected, we immediately go to the site to check. If a fire is found, it will promptly be extinguished," Yusuf said. The use of this drone represents a preparedness measure by UB Forest management to prevent fires amidst an increasingly drier dry season.Such dry conditions necessitate more intensive monitoring patterns. The team utilized the technology to monitor the area between August 25 and 27, 2026, yielding results when a fire was detected just outside the sitespecifically in the border zone between UB Forest and the adjacent to forest area. Nevertheless, Yusuf noted that findings from aerial monitoring remain a concern for personnel, as the fire could potentially spread into UB Forest if not addressed quickly. He added that the detected fire was successfully brought under control and extinguished. Afterward, personnel conducted a sweep to ensure no new hotspots emerged, including within the UB Forest area itself. Thankfully, everything is still safe; the team conducted another check using drones, and nothing was found, he said. In an effort to safeguard the forest area, management involves local farmers who cultivate the land through a cooperation agreement scheme.Rifqi Rahmat Hidayatullah, the Coordinator of Functional Position Group (KJF) for Education, Training, and Development at UB Forest Management Unit (UPT), explained that the use of thermal drones is one way to extend the reach and strengthen patrolswhich are traditionally conducted on the groundto detect potential fires. Foot or motorcycle patrols have limited range, he noted. He further explained that the Matrice 30T thermal drone is equipped with sensors which capable of detecting surface temperatures. When an area with a higher temperature than its surroundings is detected, officers can direct the drone to that location to inspect it using the device's zoom-capable camera. Yulianto Muji Nugroho, an Educational Laboratory Technician (PLP) at UB Forest, stated that in a single flight, the drone can cover an area of approximately 10 hectares, with a maximum monitoring range of about 500 meters. This capability allows officers to monitor a wider area from the air. In one flight, the Matrice 30T can cover an area of around 10 hectares, with a maximum monitoring range of about 500 meters of 60-80 ht. This reach helps officers gain an initial overview of the area's condition without having to manually sweep the entire site. “Although this thermal drone helps in detection, its flight duration is limitedlasting a maximum of about 30 minutes per flight. Conducting longer patrols requires additional batteries and a schedule of two patrols per week. he said. Due to these limitations, the drone serves as a supporting tool within the early detection system rather than a replacement for field patrols.Despite the use of technology, UB Forest managers recognize that fire mitigation still requires public awareness. For more information, please click https://www.ub.ac.id/en/ Brawijaya University: https://prasetya.ub.ac.id Copyright © ANTARA 2026
- Math Enrichment Program North Canton Ohio Develops ThinkersThe combination of structured practice, creative challenges, and reasoning activities can contribute to a stronger foundation for future learning.
- Netflix'Collision Course,' the New Film by Daniel Sánchez Arévalo, Premieres on Netflix on 30 OctoberCompanies: Netflix, Inc.The film stars Laia Costa, Karra Elejalde, Luis Zahera, Tamar Novas, Álvaro Cervantes and Lluís Homar.